Uganda Unveils Locally Produced Anti-Tick Vaccine to Boost Livestock Sector

President Yoweri Museveni has officially commissioned Uganda’s pioneering locally developed anti-tick vaccine, marking a significant advancement for the nation’s livestock industry. Launched at the National Livestock Resources Research Institute (NaLIRRI) in Namulonge, the vaccine, named NAROVAC-ATV1, is hailed as a sustainable solution to the persistent challenge of tick-borne diseases.

The Shs170 billion government-funded project addresses the severe economic impact of ticks, particularly in cattle-keeping regions, where farmers have faced substantial losses despite efforts to control these pests.

President Museveni highlighted that ticks have been a long-standing impediment to Uganda’s livestock potential. He emphasized that NAROVAC-ATV1 offers a safer and more effective alternative to traditional acaricides, which are often toxic and diminishing in efficacy over time. “The cow now kills the tick,” he stated, underscoring the innovative mechanism of the vaccine.

Recognizing the critical role of scientific innovation, the President pledged continued government support for the science sector, proposing incentives for scientists akin to those for security personnel. He also confirmed government commitment to providing the Shs600 billion requested by the National Agricultural Research Organisation (NARO) to further develop the vaccine research hub.

The Minister of Agriculture, Animal Industry and Fisheries, Hon. Frank Tumwebaze, noted that the project’s journey began in 2022 and praised the collaborative effort that led to its success. The State Minister for Animal Industry, Hon. Bright Rwamirama, acknowledged the government’s consistent investment in livestock development, observing positive growth in dairy farming and herd sizes.

Dr. Yonah Baguma, Director General of NARO, described the launch as a dual scientific and economic triumph. NAROVAC-ATV1 is expected to safeguard Uganda’s approximately 16 million cattle, reduce the dependence on imported vaccines and acaricides, and position the country as a regional leader in veterinary vaccine production. The facility is capable of producing up to 36 million doses annually, with current output at approximately 3 million doses per month. So far, 1.5 million doses have been produced, and there is already international interest from neighboring countries.

The vaccine is a recombinant product utilizing locally derived tick antigens. It is administered to cattle from one month of age, with an initial three-dose regimen and subsequent annual boosters, providing a full year of protection.

The National Drug Authority (NDA) confirmed that the manufacturing facility adheres to required standards, having provided technical oversight throughout the development. Early trials have yielded positive feedback from farmers, reporting reduced tick infestations and decreased treatment expenses. The vaccine is anticipated to cost around Shs10,000 per dose, making it an accessible option for farmers, thereby significantly boosting the productivity and economic viability of Uganda’s livestock sector.

This breakthrough was officially launched on April 30, 2024. Source: State House (Uganda)